CASSAVA SCIENCES INC — Regulatory Filings 2021

Aug 3, 2021

8-K 1 sava-20210729x8k.htm 8-K HTML document created with Certent Disclosure Management 21.2.0.2 Created on: 8/3/2021 3:32:08 PM SAVA 8K Open Label Results

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

FORM 8-K

---

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) July 29 , 20 2 1

---

Cassava Sciences, Inc.

(Exact name of registrant as specified in its charter)

---

Delaware	000-29959	91-1911336
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)

7801 N Capital of Texas Highway, Suite 260

Austin, Texas 78731

(Address of principal executive offices, including zip code)

(512) 501-2444

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report.)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):


☐	Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))
☐	Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

0 — Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value	SAVA	N asdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ☐

Item 7.01. Regulation FD Disclosure.

A copy of the Cassava Sciences, Inc. presentation at the 2021 Alzheimer’s Association International Conference (AAIC) is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference .

Item 8.01. Other Events.

On July 29 , 20 2 1 , Cassava Sciences, Inc. issued two press release s , cop ies of which are attached hereto as Exhibit s 99.2 and 99.3 and are incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.


(d) Exhibit No. Description

 99.1	Cassava Sciences, Inc. 2021 AAIC presentation
 99.2	Cassava Sciences, Inc. 2021 AAIC Cognition Results press release , dated Jul y 29 , 202 1
 99.3	Cassava Sciences, Inc. 2021 AAIC Biomarker Results press release , dated July 29, 2021

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 — 	Cassava Sciences, Inc.
	a Delaware corporation
Date: August 3 , 20 2 1
	By:	/s/ ERIC J. SCHOEN
		Eric J. Schoen
		Chief Financial Officer